{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:17:21Z","timestamp":1770495441146,"version":"3.49.0"},"reference-count":54,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der Keimzelltumor des Hodens ist ein Musterbeispiel f\u00fcr die Verwendung von Serum-Tumormarkern. Das Dilemma ist, dass die aktuellen Marker beta Human Chorion Gonadotropin (bHCG) und Alpha Fetoprotein (AFP) sowie Laktatdehydrogenase (LDH) nur etwa bei 50% aller Keimzelltumoren erh\u00f6ht sind. Im Jahre 2011 wurde erstmals die microRNA-371a-3p (M371) als neuer Tumormarker vorgeschlagen. MicroRNAs sind kleine RNA-Fragmente von 18\u201324 Basenpaaren, die eine epigenetische Bedeutung bei der Steuerung der Proteinbiosynthese haben. Die M371 kann im Serum mit PCR-Technik gemessen werden.<\/jats:p><jats:p>Mit einem hohen Ma\u00df an formaler Evidenz konnte gezeigt werden, dass M371 eine Sensitivit\u00e4t von etwa 90% und eine Spezifit\u00e4t von \u00fcber 90% f\u00fcr Keimzelltumoren des Hodens aufweist. Die M371 ist dabei f\u00fcr Seminome und Nichtseminome gleicherma\u00dfen sensitiv und spezifisch. Allerdings exprimieren Teratome den Marker nicht, wie auch nichtgerminale Hodentumoren und Karzinome anderer Organe. Der Marker weist eine sehr kurze Halbwertszeit von &lt;24 Stunden auf.<\/jats:p><jats:p>In naher Zukunft darf erwartet werden, dass der Test substanzielle Hilfe geben wird bei vielen klinischen Entscheidungssituationen, die bisher nur unbefriedigend zu l\u00f6sen waren. Dies d\u00fcrfte vor allem f\u00fcr die folgenden sechs Szenarien zutreffen: (1) Abkl\u00e4rung eines zuf\u00e4llig entdeckten kleinen Hodentumors mit Weichenstellung in Richtung organerhaltender Exzision versus Ablatio testis; (2) Vereinfachung der Nachsorge von Hodentumoren durch Reduktion der Bildgebung; (3) Einsch\u00e4tzung unklarer Lymphknotenvergr\u00f6\u00dferungen im Rahmen des klinischen Stagings; (4) Abkl\u00e4rung von unklaren (falsch positiven) Erh\u00f6hungen der klassischen Tumormarker; (5) rasche Beurteilung des Ansprechens auf Therapie aufgrund der kurzen Halbwertszeit; (6) Hilfe bei der Entscheidungsfindung f\u00fcr die Behandlung von Residualtumoren nach Chemotherapie, insbesondere bei Resttumoren des Seminoms.<\/jats:p><jats:p>Die Entdeckung und Entwicklung des Tumormarkers M371 stellt einen Meilenstein dar bei der Ausformung pragmatischer Therapiekonzepte f\u00fcr Keimzelltumoren.<\/jats:p>","DOI":"10.1055\/a-2358-8355","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T23:06:01Z","timestamp":1723503961000},"page":"510-519","source":"Crossref","is-referenced-by-count":1,"title":["Hodentumor \u2013 welche Vorteile bringt der neue Tumormarker microRNA-371a-3p (M371-Test)"],"prefix":"10.1055","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-7956","authenticated-orcid":false,"given":"Klaus-Peter","family":"Dieckmann","sequence":"additional","affiliation":[{"name":"Urologie, Asklepios Klinik Altona, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gazanfer","family":"Belge","sequence":"additional","affiliation":[{"name":"Universit\u00e4t Bremen, Institut f\u00fcr Tumordiagnostik, Bremen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3238\/arztebl.m2023.0143","article-title":"Testicular Tumors: High Likelihood of Cure With Interdisciplinary Management","volume":"120","author":"S Krege","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000510407","article-title":"Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages","volume":"105","author":"S Kliesch","year":"2021","journal-title":"Urol Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology Guidelines on Testicular Cancer: 2023 Update","volume":"84","author":"A Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM197611252952207","article-title":"Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer","volume":"295","author":"PH Lange","year":"1976","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00120-010-2414-5","article-title":"Markersysteme beim Hodentumor","volume":"50","author":"S Krege","year":"2011","journal-title":"Urologe A"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5030349","DOI":"10.1155\/2019\/","article-title":"Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment","volume":"2019","author":"KP Dieckmann","year":"2019","journal-title":"BioMed Res Int"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/1097-0142(19870801)60:3+<464::aid-cncr2820601506>3.0.co;2-c","article-title":"Biological markers in urologic cancer","volume":"60","author":"PH Lange","year":"1987","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"RC Lee","year":"1993","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ydbio.2004.02.019","article-title":"Human embryonic stem cells express a unique set of microRNAs","volume":"270","author":"MR Suh","year":"2004","journal-title":"Dev Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1387\/ijdb.130020re","article-title":"Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer","volume":"57","author":"R Eini","year":"2013","journal-title":"Int J Dev Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/978-0-387-69116-9_2","article-title":"A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors","volume":"124","author":"PM Voorhoeve","year":"2006","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1309\/AJCPOE11KEYZCJHT","article-title":"Identification of microRNAs From the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors","volume":"135","author":"MJ Murray","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.eururo.2012.02.037","article-title":"Serum Levels of MicroRNAs miR-371\u20133: A Novel Class of Serum Biomarkers for Testicular Germ Cell Tumors?","volume":"61","author":"G Belge","year":"2012","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/bjc.2012.469","article-title":"MicroRNAs miR-371\u20133 in serum as diagnostic tools in the management of testicular germ cell tumours","volume":"107","author":"KP Dieckmann","year":"2012","journal-title":"Br J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.molonc.2013.08.002","article-title":"Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: A proof of principle","volume":"7","author":"AJ Gillis","year":"2013","journal-title":"Mol Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.juro.2014.07.010","article-title":"Circulating serum microRNA (miR-367\u20133p, miR-371a-3p, miR-372\u20133p, miR-373\u20133p) as biomarkers for patients with testicular germ cell cancers","volume":"193","author":"I Syring","year":"2015","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"58037","DOI":"10.18632\/oncotarget.10867","article-title":"Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test)","volume":"8","author":"T van Agthoven","year":"2017","journal-title":"Oncotarget"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2016.07.029","article-title":"Serum Levels of MicroRNA 371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumors","volume":"71","author":"KP Dieckmann","year":"2017","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fgene.2019.00463","article-title":"Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis","volume":"10","author":"MP Myklebust","year":"2019","journal-title":"Front Genet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"15582","DOI":"10.1038\/s41598-021-94812-2","article-title":"Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study","volume":"11","author":"MP Myklebust","year":"2021","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"876732","DOI":"10.3389\/fonc.2022.","article-title":"DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients","volume":"12","author":"JP Sequeira","year":"2022","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell-tumors: Results of a prospective multicentric study","volume":"37","author":"KP Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00432-020-03429-x","article-title":"Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin","volume":"147","author":"G Belge","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.2047-2927.2014.00269.x","article-title":"MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker","volume":"3","author":"M Spiekermann","year":"2015","journal-title":"Andrology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3390\/cancers12030759","article-title":"Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up-A Copenhagen Experience","volume":"12","author":"N M\u00f8rup","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.3390\/cancers14215447","article-title":"Testicular neoplasms: primary tumour size is closely interrelated with histology, clinical staging, and tumour marker expression rates \u2013 a comprehensive statistical analysis","volume":"14","author":"KP Dieckmann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/JU.0000000000001337","article-title":"Real-World Application of Pre-orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management","volume":"205","author":"RR Badia","year":"2021","journal-title":"J Urol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000488771","article-title":"The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1","volume":"100","author":"A Radtke","year":"2018","journal-title":"Urol int"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/cells8121637","article-title":"Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data","volume":"8","author":"J Lobo","year":"2019","journal-title":"Cells"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"20170338","DOI":"10.1098\/rstb.2017.0338","article-title":"Germ cell tumour subtypes display differential expression of microRNA371a-3p","volume":"373","author":"B Vilela-Salgueiro","year":"2018","journal-title":"Philos Trans R Soc B"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2018.02.068","article-title":"Serum miRNA predicts viable disease post-chemotherapy in testicular non-seminoma germ cell tumor patients","volume":"200","author":"R Le\u00e3o","year":"2018","journal-title":"J Urol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.21873\/invivo.11757","article-title":"Serum Level of microRNA-375\u20133p Is Not a Reliable Biomarker of Teratoma","volume":"34","author":"G Belge","year":"2020","journal-title":"In Vivo"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.euros.2021.02.003","article-title":"Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection","volume":"26","author":"JT Lafin","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.3390\/cancers15153944","article-title":"MicroRNA-371a-3p \u2013The Novel Serum Biomarker in Testicular Germ Cell Tumors","volume":"15","author":"T Nestler","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/bju.14056","article-title":"Incidentally detected testicular lesions <10 mm in diameter: can orchidectomy be avoided?","volume":"121","author":"G Scandura","year":"2017","journal-title":"BJU Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bju.16040","article-title":"Validation of a Prediction Model for Post-chemotherapy Fibrosis in Nonseminoma Patients","volume":"132","author":"A Gerdtsson","year":"2023","journal-title":"BJU Int"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000511245","article-title":"Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II \u2013 Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord\/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy","volume":"105","author":"S Kliesch","year":"2021","journal-title":"Urol Int"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12957-020-02032-1","article-title":"Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature","volume":"18","author":"CG Ruf","year":"2020","journal-title":"W J Surg Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/cells8101221","article-title":"miR-371a-3p, miR-373\u20133p and miR-367\u20133p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy","volume":"8","author":"X Rosas Plaza","year":"2019","journal-title":"Cells"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"889624","DOI":"10.3389\/fonc.2022","article-title":"Serum levels of microRNA 371a-3p (M371) can predict absence or presence of vital disease in residual masses after chemotherapy of metatstatic seminoma","volume":"12","author":"KP Dieckmann","year":"2022","journal-title":"Front Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euros.2023.01.013.","article-title":"The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study","volume":"50","author":"S Fischer","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.jacr.2022.02.009","article-title":"ACR Appropriateness Criteria\u00ae Staging and Surveillance of Testicular Cancer: 2021 Update","volume":"19","author":"N Schieda","year":"2022","journal-title":"J Am Coll Radiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.3390\/ijms19103130","article-title":"MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients","volume":"19","author":"A Terbuch","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jmoldx.2022.04.007","article-title":"Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372\u20133p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting","volume":"24","author":"F Ye","year":"2022","journal-title":"J Mol Diagn"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41416-021-01643-z","article-title":"Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours","volume":"126","author":"CD Fankhauser","year":"2022","journal-title":"Br J Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euo.2020.11.004","article-title":"Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer","volume":"4","author":"J Lobo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/078-0432.CCR-23-730.","article-title":"Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study","volume":"30","author":"G Belge","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ncrna6010002","article-title":"MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients","volume":"6","author":"AL Lembeck","year":"2020","journal-title":"Noncoding RNA"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.eururo.2017.12.026","article-title":"Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer","volume":"73","author":"SC Kamran","year":"2017","journal-title":"Eur Urol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2019.10.005","article-title":"Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-na\u00efve Patients Undergoing Retroperitoneal Lymph Node Dissection","volume":"77","author":"JT Lafin","year":"2020","journal-title":"Eur Urol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.euo.2023.10.021","article-title":"Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA\/B Seminoma or Nonseminoma","volume":"7","author":"F Seelemeyer","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"vdaa048","DOI":"10.1093\/noajnl\/vdaa048","article-title":"Clinical Utility of Circulating miR-371a-3p for the Management of Patients With Intracranial Malignant Germ Cell Tumors","volume":"2","author":"MJ Murray","year":"2020","journal-title":"Neurooncol Adv"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00432-022-3915-4.","article-title":"MicroRNA-profiling of miR-371~373- and miR-302\/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors","volume":"149","author":"S Sch\u00f6nberger","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1200\/JCO.18.02057","article-title":"Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum","volume":"37","author":"L Nappi","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2358-8355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:37:02Z","timestamp":1733269022000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2358-8355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":54,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,12,3]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2358-8355","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]}}}